U.S. Markets open in 8 hrs 15 mins

Enzo Biochem, Inc. (ENZ)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
2.9200-0.0800 (-2.67%)
At close: 4:00PM EDT

Enzo Biochem, Inc.

527 Madison Avenue
New York, NY 10022
United States
212 583 0100
http://www.enzo.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees408

Key Executives

NameTitlePayExercisedYear Born
Dr. Elazar RabbaniCo-Founder, Chairman, CEO & Sec.1.31MN/A1943
Mr. Barry W. WeinerFounder, Treasurer & Pres1.09MN/A1950
Mr. David A. BenchCFO & Principal Accounting Officer213.67kN/AN/A
Ms. Kara CannonChief Commercial Officer293.05kN/A1968
Dr. Dieter SchapfelChief Medical Director of Enzo Clinical Labs403.53kN/A1963
Mr. Bruce A. DeyVP of Sales & Marketing - Enzo Clinical LabsN/AN/A1958
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing ‘STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

Corporate Governance

Enzo Biochem, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 8. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.